+44 20 8123 2220
info@marketpublishers.com

Diabetes Drug Market, Oral (DPP IV Inhibitor, SGLT-2, Alpha Glucosidase Inhibitor, Biguanide) Injection (Glucagon-like peptide (GLP) 1 agonist, Amylin Receptor Agonist), Insulin (Rapid – Acting Insulin, Long Acting Insulin, Premixed Insulin), Regions (United States, Europe, Japan, China, India, Brazil), Companies (Novo Nordisk, Merck & Co, Eli Lilly, AstraZeneca, Johnson & Johnson, Boehringer Ingelheim)

https://marketpublishers.com/r/DCAD7122A55EN.html
Date: November 2018
Pages: 0
Price: US$ 1,990.00 (Single User License)
ID: DCAD7122A55EN

Abstracts

Global diabetes drug market is expected to surpass US$ 76 Billion by the end of year 2024. Rising global diabetes prevalence like Type 1 diabetes and Type 2 diabetes is the major reason for growth of diabetes drug market. Type 2 diabetes is on the rise globally due to growth in obesity trends, sedentary lifestyle and lack of physical activity. Type1 diabetes patient requires less amount diabetes drug, whereas Type 2 diabetes patient are massive consumer of diabetes drug. Several companies are creating their diabetes drug pipeline and trying to broaden their diabetes drug portfolio which will further boost the global diabetes drug market in forecast period.

Diabetes is condition in which the patient has a high blood sugar level over a long drawn period. There are 3 types of diabetes Type 1 diabetes, Type 2 diabetes and Gestational diabetes. Type 1 diabetes is a condition in which patient pancreas fail to produce enough insulin. It is also called juvenile diabetes. In Type 2 diabetes body cells fails to respond to insulin properly. Third one is Gestational diabetes in which a pregnant woman with no history of diabetes develops high blood sugar level. Globally 90% of the diabetes patients are Type 2 and rest are Type 1 cases.

Renub Research report titled “Diabetes Drug Market, Oral (DPP IV Inhibitor, SGLT-2, Alpha Glucosidase Inhibitor, Biguanide) Injection (Glucagon-like peptide (GLP) 1 agonist, Amylin Receptor Agonist), Insulin (Rapid – Acting Insulin, Long Acting Insulin, Premixed Insulin), Regions (United States, Europe, Japan, China, India, Brazil), Companies (Novo Nordisk, Merck & Co, Eli Lilly, AstraZeneca, Johnson & Johnson, Boehringer Ingelheim)” provides a complete analysis of Diabetes Drug Market.

Type 2 Diabetes Patients has bigger Consumer Base

In this report, we have categorized the diabetes drug market into two part; type 1 diabetes drug market and type 2 diabetes drug markets. (DPP) IV Inhibitor Segment has the largest Market in Global Diabetes Drug Market

According to Renub Research this report provides in-depth analysis of diabetes drug market form multiple perspectives. Here the global diabetes drug market has been categorized into 3 segments: Oral Diabetes Drug Market, Injectable Diabetes Drug Market and Insulin.

> Oral Diabetes Drug Market is further sub-divided into 5 categories by drug class- (DPP) IV Inhibitor, SGLT-2, Alpha Glucosidase Inhibitor, Biguanide and Other Oral Drug market.
>
> Injectable Diabetes Drug Market has been further classified into 2 parts - Glucagon-like peptide (GLP) 1 agonist and Amylin receptor agonist market.
>
> Insulin Market has been further categorized into 4 parts - Rapid – Acting Insulin market, Long Acting Insulin market, Premixed Insulin market and Other Insulin market.

United States dominates the Global diabetes drug Market

The regions covered in the report for of type 1 diabetes drug market are United States, European Union (France, Germany, Italy, Spain and United Kingdom), Japan and Canada.

The regions covered for type 2 diabetes drug market - are United States, European Union (France, Germany, Italy, Spain and United Kingdom), Japan, China, India and

Brazil. In addition, we have also covered diabetes population of each of these covered regions along with Type 1 and Type 2 diabetes populations.

Novo Nordisk is the Largest Player in Global Diabetes Drug Market

In this report, published by Renub Research a comprehensive assessment of global diabetes drug revenue by five major key players is covered. The key players covered in the report are Novo Nordisk, Merck & Co, Eli Lilly, AstraZeneca, Johnson & Johnson and Boehringer Ingelheim. This report covers historical sales analysis and forecast along with major factors like diabetes R&D and pipeline of diabetes drug in separate chapter.

Disease Type - Global Diabetes Drug Market

1. By Type 1 Diabetes Drug Market
2. By Type 2 Diabetes Drug Market

Product - Global Diabetes Drug Market

Oral

1. (DPP) IV inhibitor
2. SGLT-2
3. Alpha Glucosidase Inhibitor
4. Biguanide
5. Others Oral Drug

Injection

1. Glucagon-like peptide (GLP) 1 agonist
2. Amylin receptor agonist

Insulin

1. Rapid – Acting Insulin
2. Long Acting Insulin
3. Premixed Insulin
4. Other Insulin

+44 20 8123 2220
info@marketpublishers.com

Regions - Population Type 1 & Type 2 Diabetes Drug

1. United States
2. 5 European Union (France, Germany, Italy, Spain and United Kingdom)
3. Japan
4. China
5. India
6. Brazil

Regions - Type 1 Diabetes Drug Market

1. United States
2. 5 European Union (France, Germany, Italy, Spain and United Kingdom)
3. Japan
4. Canada

Regions - Type 2 Diabetes Drug Market

1. United States
2. 5 European Union (France, Germany, Italy, Spain and United Kingdom)
3. Japan
4. China
5. India
6. Brazil

Key Players Analysis

1. Novo Nordisk
2. Merck & Co
3. Eli Lilly
4. AstraZeneca
5. Johnson & Johnson
6. Boehringer Ingelheim

+44 20 8123 2220
info@marketpublishers.com

Contents

1. INTRODUCTION

1.1 Market Definition
1.2 Currency Conversion

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. GLOBAL DIABETES DRUG MARKET

5. MARKET SHARE – GLOBAL DIABETES DRUG

5.1 Disease Type
5.2 Therapy – (Oral, Injection, Insulin)
5.3 Oral Drug
5.4 Injection Drug
5.5 Insulin
5.6 Regions – Type 1 Diabetes Drug
5.7 Regions – Type 2 Diabetes Drug

6. DISEASE TYPE – GLOBAL DIABETES DRUG MARKET

6.1 Type 1 Diabetes
6.2 Type 2 Diabetes

7. THERAPY – GLOBAL DIABETES DRUG MARKET

7.1 Oral Drugs Market
  7.1.1 (DPP) IV Inhibitor
  7.1.2 SGLT-2
  7.1.3 Alpha Glucosidase Inhibitor
  7.1.4 Biguanide
  7.1.5 Others Oral Drug
7.2 Injectable Drugs Market
  7.2.1 Glucagon-like peptide (GLP) 1 agonist
  7.2.2 Amylin Receptor Agonist

+44 20 8123 2220
info@marketpublishers.com

7.3 Insulin Market
7.3.1 Rapid – Acting Insulin
7.3.2 Long Acting Insulin
7.3.3 Premixed Insulin
7.3.4 Other Insulin

8. REGION – TYPE 1 DIABETES DRUG MARKET

8.1 United States
8.2 European Union
8.3 Japan
8.4 Canada

9. REGION – TYPE 2 DIABETES DRUG MARKET

9.1 United States
9.2 European Union
9.3 Japan
9.4 China
9.5 India
9.6 Brazil

10. REGIONS – DIABETIC POPULATION

10.1 United States
10.1.1 Type
10.1.2 Type
10.2 European Union
10.2.1 Type
10.2.2 Type
10.3 Japan
10.3.1 Type
10.3.2 Type
10.4 Canada
10.4.1 Type
10.4.2 Type
10.5 China
10.5.1 Type
10.6 India

10.6.1 Type
10.7 Brazil
10.7.1 Type

11. KEY PLAYERS ANALYSIS

11.1 Novo Nordisk Overview
11.1.1 R&D Pipeline
11.1.2 Sales Analysis
11.2 Merck & Co Overview
11.2.1 R&D Pipeline
11.2.2 Sales Analysis
11.3 Eli Lilly Overview
11.3.1 R&D Pipeline
11.3.2 Sales Analysis
11.4 AstraZeneca Overview
11.4.1 R&D Pipeline
11.4.2 Sales Analysis
11.5 Johnson & Johnson Overview
11.5.1 R&D Pipeline
11.5.2 Sales Analysis
11.6 Boehringer Ingelheim Overview
11.6.1 R&D Pipeline
11.6.2 Sales Analysis

12. MERGERS & ACQUISITIONS

13. MARKET DYNAMICS

13.1 Growth Drivers
13.1.1 Rising Prevalence of Diabetes
13.1.2 Rising Cost of Diabetes Care
13.2 Challenges
13.2.1 Controversy regarding Clinical Benefits
13.3 Opportunities

+44 20 8123 2220
info@marketpublishers.com

List Of Figures

LIST OF FIGURES:

Figure-01: Global – Diabetes Drugs Market size (Million US$), 2018 & 2024
Figure-02: Global – Diabetes Drugs Growing Segments
Figure-03: Global – Diabetes Drugs Market (Million US$), 2016 – 2017
Figure-04: Global – Forecast for Diabetes Drugs Market(Million US$), 2018 – 2024
Figure-05: Global – Diabetes Drugs Market Share by Disease type (Percent), 2016 – 2017
Figure-06: Global – Forecast for Diabetes Drugs Market Share by disease type(Percent), 2018 – 2024
Figure-07: Global – Diabetes Drugs Market Share by Therapy (Percent), 2016 – 2017
Figure-08: Global – Forecast for Diabetes Drugs Market Share by Therapy (Percent), 2018 – 2024
Figure-09: Global – Diabetes Drugs Market Share by Oral Drug (Percent), 2016 – 2017
Figure-10: Global – Forecast for Diabetes Drugs Market Share by Oral Drug (Percent), 2018 – 2024
Figure-11: Global – Diabetes Drugs Market Share by Injectable Drug (Percent), 2016 – 2017
Figure-12: Global – Forecast for Diabetes Drugs Market Share by Injectable Drug (Percent), 2018 – 2024
Figure-13: Global – Diabetes Drugs Market Share by Insulin (Percent), 2016 – 2017
Figure-14: Global – Forecast for Diabetes Drugs Market Share by Insulin (Percent), 2018 – 2024
Figure-15: Global – Diabetes Drugs Market Share type1 Diabetes Drug by Regions (Percent), 2016 – 2017
Figure-16: Global – Forecast for Diabetes Drugs Market Share type1 Diabetes Drug by Regions (Percent), 2018 – 2024
Figure-17: Global – Diabetes Drugs Market Share type2 Diabetes Drug by Regions (Percent), 2016 – 2017
Figure-18: Global – Forecast for Diabetes Drugs Market Share type2 Diabetes Drug by Regions (Percent), 2018 – 2024
Figure-19: Global – Diabetes Drug Market by type1 Diabetes (Million US$), 2016 – 2017
Figure-20: Global – Forecast for Diabetes Drug Market by type1 Diabetes (Million US$), 2018 – 2024
Figure-21: Global – Diabetes Drug Market by type2 Diabetes (Million US$), 2016 – 2017
Figure-22: Global – Forecast for Diabetes Drug Market by type2 Diabetes (Million US$), 2018 – 2024

Figure-23: Global – Oral Drug (DPP) IV inhibitor Market (Million US$), 2016 – 2017
Figure-24: Global – Forecast for Oral Drug (DPP) IV inhibitor Market (Million US$), 2018 – 2024
Figure-25: Global – Oral Drug SGLT-2 Market (Million US$), 2016 – 2017
Figure-26: Global – Forecast for Oral Drug SGLT-2 Market (Million US$), 2018 – 2024
Figure-27: Global – Oral Drug Alpha Glucosidase Inhibitor Market (Million US$), 2016 – 2017
Figure-28: Global – Forecast for Oral Drug Alpha glucosidase inhibitor Market (Million US$), 2018 – 2024
Figure-29: Global – Oral Drug Biguanide Market (Million US$), 2016 – 2017
Figure-30: Global – Forecast for Oral Drug Biguanide Market (Million US$), 2018 – 2024
Figure-31: Global – Oral Drug Others Market (Million US$), 2016 – 2017
Figure-32: Global – Forecast for Oral Drug Others Market (Million US$), 2018 – 2024
Figure-33: Global – Diabetes Injectable Drug Glucagon-like peptide (GLP) 1 agonist Market (Million US$), 2016 – 2017
Figure-34: Global – Forecast for Diabetes Injectable Drug Glucagon-like peptide (GLP) 1 agonist Market (Million US$), 2018 – 2024
Figure-35: Global – Diabetes Injectable Drug Amylin receptor agonist Market (Million US$), 2016 – 2017
Figure-36: Global – Forecast for Diabetes Injectable Drug Amylin receptor agonist Market (Million US$), 2018 – 2024
Figure-37: Global – Diabetes Insulin Drug Rapid Acting (Fast Acting) Market (Million US$), 2016 – 2017
Figure-38: Global – Forecast for Diabetes Insulin Drug Rapid Acting (Fast Acting) Market (Million US$), 2018 – 2024
Figure-39: Global – Diabetes Insulin Drug Long Acting Market (Million US$), 2016 – 2017
Figure-40: Global – Forecast for Diabetes Insulin Drug Long Acting Market (Million US$), 2018 – 2024
Figure-41: Global – Diabetes Insulin Drug Premixed Market (Million US$), 2016 – 2017
Figure-42: Global – Forecast for Diabetes Insulin Drug Premixed Market (Million US$), 2018 – 2024
Figure-43: Global – Diabetes Drug Other Insulin (Including Human Insulin) Market (Million US$), 2016 – 2017
Figure-44: Global – Forecast for Diabetes Drug Other Insulin (Including Human Insulin) Market (Million US$), 2018 – 2024
Figure-45: United States – type1 Diabetes Drug Market (Million US$), 2016 – 2017
Figure-46: United States – Forecast for Type1 Diabetes Drug Market (Million US$), 2018 – 2024

Figure-47: 5 European Union – type 1 Diabetes Drug Market (Million US$), 2016 – 2017
Figure-48: 5 European Union – Forecast for type 1 Diabetes Drug Market (Million US$), 2018 – 2024
Figure-49: Japan – type1 Diabetes Drug Market (Million US$), 2016 – 2017
Figure-50: Japan – Forecast for type1 Diabetes Drug Market (Million US$), 2018 – 2024
Figure-51: Canada – type 1 Diabetes Drug Market (Million US$), 2016 – 2017
Figure-52: Canada – Forecast for type1 Diabetes Drug Market (Million US$), 2018 – 2024
Figure-53: United States – type2 Diabetes Drug Market (Million US$), 2016 – 2017
Figure-54: United States – Forecast for type2 Diabetes Drug Market (Million US$), 2018 – 2024
Figure-55: 5 European Union – type2 Diabetes Drug Market (Million US$), 2016 – 2017
Figure-56: 5 European Union – Forecast for type2 Diabetes Drug Market (Million US$), 2018 – 2024
Figure-57: Japan – type2 Diabetes Drug Market (Million US$), 2016 – 2017
Figure-58: Japan – Forecast for type2 Diabetes Drug Market (Million US$), 2018 – 2024
Figure-59: China – type2 Diabetes Drug Market (Million US$), 2016 – 2017
Figure-60: China – Forecast for type2 Diabetes Drug Market (Million US$), 2018 – 2024
Figure-61: India – type2 Diabetes Drug Market (Million US$), 2016 – 2017
Figure-62: India – Forecast for type2 Diabetes Drug Market (Million US$), 2018 – 2024
Figure-63: Brazil – type2 Diabetes Drug Market (Million US$), 2016 – 2017
Figure-64: Brazil – Forecast for type2 Diabetes Drug Market (Million US$), 2018 – 2024
Figure-65: United States – Diabetes Population (Thousands), 2010 – 2017
Figure-66: United States – Forecast for Diabetes Population (Thousands), 2018 – 2024
Figure-67: United States – type1 Diabetes Population (Thousands), 2010 – 2017
Figure-68: United States – Forecast for type1 Diabetes Population (Thousands), 2018 – 2024
Figure-69: United States – type2 Diabetes Population (Thousands), 2010 – 2017
Figure-70: United States – Forecast for type2 Diabetes Population (Thousands), 2018 – 2024
Figure-71: European Union – Diabetes Population (Thousands), 2010 – 2017
Figure-72: European Union – Forecast for Diabetes Population (Thousands), 2018 – 2024
Figure-73: 5 European Union – type1 Diabetes Population (Thousands), 2010 – 2017
Figure-74: 5 European Union – Forecast for type1 Diabetes Population (Thousands), 2018 – 2024
Figure-75: European Union – type2 Diabetes Population (Thousands), 2010 – 2017
Figure-76: European Union – Forecast for type2 Diabetes Population (Thousands), 2018 – 2024

Figure-77: Japan – Diabetes Population (Thousands), 2010 – 2017
Figure-78: Japan – Forecast for Diabetes Population (Thousands), 2018 – 2024
Figure-79: Japan – Type1 Diabetes Population (Thousands), 2010 – 2017
Figure-80: Japan – Forecast for type1 Diabetes Population (Thousands), 2018 – 2024
Figure-81: Japan – Type2 Diabetes Population (Thousands), 2010 – 2017
Figure-82: Japan – Forecast for Type2 Diabetes Population (Thousands), 2018 – 2024
Figure-83: Canada – Diabetes Population (Thousands), 2010 – 2017
Figure-84: Canada – Forecast for Diabetes Population (Thousands), 2018 – 2024
Figure-85: Canada – type1 Diabetes Population (Thousands), 2010 – 2017
Figure-86: Canada – Forecast for type1 Diabetes Population (Thousands), 2018 – 2024
Figure-87: China – type2 Diabetes Population (Thousands), 2010 – 2017
Figure-88: China – Forecast for type2 Diabetes Population (Thousands), 2018 – 2024
Figure-89: India – type2 Diabetes Population (Thousands), 2010 – 2017
Figure-90: India – Forecast for type2 Diabetes Population (Thousands), 2018 – 2024
Figure-91: Brazil – Diabetes Population (Thousands), 2010 – 2017
Figure-92: Brazil – Forecast for Diabetes Population (Thousands), 2018 – 2024
Figure-93: Global – Novo Nordisk Diabetes Drug Sales (Million US$), 2015 – 2017
Figure-94: Global – Forecast for Novo Nordisk Diabetes Drug Sales (Million US$), 2018 – 2024
Figure-95: Global – Merck & Co Diabetes Drug Sales (Million US$), 2015 – 2017
Figure-96: Global – Forecast for Merck & Co Diabetes Drug Sales (Million US$), 2018 – 2024
Figure-97: Global – Eli Lilly Diabetes Drug Sales (Million US$), 2015 – 2017
Figure-98: Global – Forecast for Eli Lilly Diabetes Drug Sales (Million US$), 2018 – 2024
Figure-99: Global – AstraZeneca Diabetes Drug Sales (Million US$), 2015 – 2017
Figure-100: Global – Forecast for AstraZeneca Diabetes Drug Sales (Million US$), 2018 – 2024
Figure-101: Global – Johnson & Johnson Diabetes Drug Sales (Million US$), 2015 – 2017
Figure-102: Global – Forecast for Johnson & Johnson Diabetes Drug Sales (Million US$), 2018 – 2024
Figure-103: Global – Boehringer Ingelheim Diabetes Drug Sales (Million US$), 2015 – 2017
Figure-104: Global – Forecast for Boehringer Ingelheim Diabetes Drug Sales (Million US$), 2018 – 2024

+44 20 8123 2220
info@marketpublishers.com

I would like to order

Product name: Diabetes Drug Market, Oral (DPP IV Inhibitor, SGLT-2, Alpha Glucosidase Inhibitor, Biguanide) Injection (Glucagon-like peptide (GLP) 1 agonist, Amylin Receptor Agonist), Insulin (Rapid – Acting Insulin, Long Acting Insulin, Premixed Insulin), Regions (United States, Europe, Japan, China, India, Brazil), Companies (Novo Nordisk, Merck & Co, Eli Lilly, AstraZeneca, Johnson & Johnson, Boehringer Ingelheim)

Product link: https://marketpublishers.com/r/DCAD7122A55EN.html

Price: US$ 1,990.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/DCAD7122A55EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

+44 20 8123 2220
info@marketpublishers.com

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970